KALA BIO Inc Reaches 20-Day High on New CEO and Funding Agreement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 01 Dec 25
Source: 144
KALA BIO Inc saw a significant pre-market increase of 26.28%, reaching a 20-day high. This rise follows a series of positive developments, including a securities purchase agreement to raise up to $6 million and the appointment of David Lazar as the new CEO.
The securities purchase agreement includes an initial closing that raised $1.8 million from the sale of preferred shares. Additionally, KALA BIO reached a loan settlement with Oxford Finance LLC, which will reduce its loan balance significantly.
These developments come despite broader market declines, with the Nasdaq-100 down 0.72% and the S&P 500 down 0.57%. The positive news surrounding KALA BIO indicates a potential turnaround for the company after a challenging year.
Analyst Views on KALA
About KALA
KALA BIO, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research, development, and commercialization of therapies for rare and severe diseases of the eye. The Company’s biologics-based investigational therapies utilize its proprietary mesenchymal stem cell secretome (MSC-S) platform. The Company’s product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biocfactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing, which is an underlying etiology of multiple severe ocular diseases; KPI-014 specific for inherited retinal degenerative diseases. KPI-012 is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing. The Company is also engaged in the development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
